Protagenic Therapeutics (PTIX) Competitors $0.20 -0.03 (-13.29%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$0.20 +0.00 (+2.00%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PTIX vs. ADXN, OBSV, BCLI, ONCO, KLTO, CYCN, AYTU, UPC, BTAI, and NKGNShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Addex Therapeutics (ADXN), ObsEva (OBSV), Brainstorm Cell Therapeutics (BCLI), Onconetix (ONCO), Klotho Neurosciences (KLTO), Cyclerion Therapeutics (CYCN), Aytu BioPharma (AYTU), Universe Pharmaceuticals (UPC), BioXcel Therapeutics (BTAI), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Addex Therapeutics ObsEva Brainstorm Cell Therapeutics Onconetix Klotho Neurosciences Cyclerion Therapeutics Aytu BioPharma Universe Pharmaceuticals BioXcel Therapeutics NKGen Biotech Protagenic Therapeutics (NASDAQ:PTIX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Do institutionals & insiders have more ownership in PTIX or ADXN? 8.0% of Protagenic Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 35.0% of Protagenic Therapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer PTIX or ADXN? Addex Therapeutics received 15 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformProtagenic TherapeuticsN/AN/AAddex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Which has stronger valuation and earnings, PTIX or ADXN? Protagenic Therapeutics has higher earnings, but lower revenue than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Protagenic Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagenic TherapeuticsN/AN/A-$5M-$1.27-0.15Addex Therapeutics$556.05K13.99-$11.76M-$0.34-21.59 Which has more volatility and risk, PTIX or ADXN? Protagenic Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Is PTIX or ADXN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Protagenic Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -112.43% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protagenic TherapeuticsN/A -308.97% -228.73% Addex Therapeutics 850.30%-112.43%-77.95% Does the media prefer PTIX or ADXN? In the previous week, Protagenic Therapeutics had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 3 mentions for Protagenic Therapeutics and 2 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 1.43 beat Protagenic Therapeutics' score of 0.66 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Protagenic Therapeutics Positive Addex Therapeutics Positive Do analysts rate PTIX or ADXN? Addex Therapeutics has a consensus target price of $30.00, indicating a potential upside of 308.72%. Given Addex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Addex Therapeutics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAddex Therapeutics beats Protagenic Therapeutics on 12 of the 16 factors compared between the two stocks. Remove Ads Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.41M$6.89B$5.63B$7.79BDividend YieldN/A2.81%5.37%4.04%P/E Ratio-0.157.4223.6118.68Price / SalesN/A207.04373.3989.80Price / CashN/A65.6738.1734.64Price / Book0.246.206.734.12Net Income-$5M$142.11M$3.20B$247.10M7 Day Performance-27.36%-7.28%-5.33%-3.82%1 Month Performance-36.03%-10.45%-0.40%-6.61%1 Year Performance-88.79%-12.86%7.89%-1.67% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics0.9178 of 5 stars$0.20-13.3%N/A-88.9%$1.41MN/A-0.152Earnings ReportUpcoming EarningsShort Interest ↑Gap DownADXNAddex Therapeutics2.8439 of 5 stars$7.69+0.3%$30.00+290.4%-42.7%$8.05M$556,045.00-22.6030Short Interest ↓Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageBCLIBrainstorm Cell Therapeutics3.8482 of 5 stars$1.37-2.8%$30.00+2,089.8%-85.1%$7.81MN/A-0.2940Upcoming EarningsNews CoverageGap UpONCOOnconetix0.5796 of 5 stars$0.12-6.4%N/A-98.7%$7.73M$1.87M0.0012High Trading VolumeKLTOKlotho NeurosciencesN/A$0.28-3.2%N/AN/A$7.68MN/A0.00N/AEarnings ReportGap DownCYCNCyclerion Therapeutics2.3054 of 5 stars$2.82+2.5%N/A-21.9%$7.64M$2M-2.3130Short Interest ↓Gap UpAYTUAytu BioPharma2.023 of 5 stars$1.23-0.8%N/A-60.5%$7.59M$77.23M-0.85160UPCUniverse PharmaceuticalsN/A$4.39+24.6%N/A-99.7%$7.53M$26.73M0.00220Gap DownHigh Trading VolumeBTAIBioXcel Therapeutics4.6779 of 5 stars$2.29-1.7%$42.60+1,760.3%-95.5%$7.47M$2.28M-0.0790Earnings ReportShort Interest ↓Gap DownNKGNNKGen BiotechN/A$0.17+6.4%N/A-90.5%$7.42M$80,000.00-0.03N/A Remove Ads Related Companies and Tools Related Companies Addex Therapeutics Alternatives ObsEva Alternatives Brainstorm Cell Therapeutics Alternatives Onconetix Alternatives Klotho Neurosciences Alternatives Cyclerion Therapeutics Alternatives Aytu BioPharma Alternatives Universe Pharmaceuticals Alternatives BioXcel Therapeutics Alternatives NKGen Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIX) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
